Generation of high‐expressing transposon‐based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies
Biotechnology Progress · 2026-09 · 42 (5)
DOI: 10.1002/btpr.88517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, online erschienen am 02.06.2026. Verfasst von Sara Ramos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ichnos Glenmark Innovation (IGI) Therapeutics, Antibody Discovery and Engineering Department, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Bispecific, DNA Transposable Elements, Immunoglobulin Light Chains. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Bi‐ and multispecific antibodies can deliver effective protein‐based therapeutics by enabling novel biology. Transient expression of these complex asymmetric antibody formats may become a bottleneck in providing sufficient amounts of high‐quality material for preclinical discovery and developability assessment to support candidate selection activities. In contrast, transposase‐based stable cell line generation is being recognized as a robust and rapid path to enable the evaluation of product quality from stable pool derived material. Transposase‐based systems feature a semi‐targeted integration of multiple copies of the gene(s) of interest in the host cell's genome resulting in the rapid generation of homogeneous high‐expressing (up to g/L range) stable pools after 1–3 weeks of selection phase. Here, we evaluated the Leap‐In® transposase technology for the expression of IGI's 1 + 1 and 2 + 1 bispecific, common light chain antibodies, based on IGI's proprietary BEAT® (Bispecific Engagement of Antibodies based on T cell Receptor) platform. To generate stable CHO pools expressing IGI's bispecific molecules, transposon‐based constructs expressing the common light chain and the two heavy chain genes were co‐transfected with the Leap‐In® transposase mRNA. Based on the proportion of the different chain combinations detected in the harvests, their expression levels were further optimized through vector engineering to facilitate heterodimer assembly and maximize productivity. The best pool displayed a titer of 2.33 g/L in 14‐day fed‐batch cultures, and heterodimer represented 93.8% of the expressed species. The purified antibody displayed 97.4% purity, as determined by SE‐HPLC and binding to targets within range, as determined by SPR and cell‐based affinity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ichnos Glenmark Innovation (IGI) Therapeutics, Antibody Discovery and Engineering Department, Lausanne, Switzerland.
- ATUM, Product Management Department, Newark, California, USA.
- ATUM, Cell Line Development Department, Newark, California, USA.
- ATUM, Newark, California, USA.
ORCID-Profile: Lydia N Caro
Zitieren
APA
Ramos, S., Karunakaran, S., Monney, T., Bornert, O., Reimann, A., Boldog, F., Dyson, M., Srivastava, A., Minshull, J., & Caro, L. N. (2026). Generation of high‐expressing transposon‐based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies. Biotechnology Progress, 42(5). https://doi.org/10.1002/btpr.88517
Vancouver
Ramos S, Karunakaran S, Monney T, Bornert O, Reimann A, Boldog F, et al. Generation of high‐expressing transposon‐based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies. Biotechnology Progress. 2026;42(5). doi:10.1002/btpr.88517
BibTeX
@article{Ramos2026,
author = {Ramos, Sara and Karunakaran, Surya and Monney, Thierry and Bornert, Olivier and Reimann, Andreas and Boldog, Ferenc and Dyson, Michael and Srivastava, Ankita and Minshull, Jeremy and Caro, Lydia N},
title = {Generation of high‐expressing transposon‐based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies},
journal = {Biotechnology Progress},
year = {2026},
volume = {42},
number = {5},
doi = {10.1002/btpr.88517}
}
EUVIMED